Selecting antipsychotics in schizophrenia: lessons from CATIE

Ahmer S , Arya P , Anderson D , Faruqui R (2005) Conflict of interest in psychiatry . Psychiatr Bull 29: 302–304

Bilder R M , Goldman R S , Volavka J , Czobor P , Hoptman M , Sheitman B , Lindenmayer J P , Citrome L , McEvoy J , Kunz M , Chakos M , Cooper T B , Horowitz T L , Lieberman J A (2002) Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder . Am J Psychiatry 159: 1018–1028

Coley K C , Carter C S , DaPos S V , Maxwell R , Wilson J W , Branch R A (1999) Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol . J Clin Psychiatry 60: 850–856

Davis J M , Chen N (2004) Dose response and dose equivalence of antipsychotics . J Clin Psychopharmacol 24: 192–208

Davis J M , Chen N , Glick I D (2003) A meta-analysis of the efficacy of second-generation antipsychotics . Arch Gen Psychiatry 60: 553–564

Gaebel W , Weinmann S , Sartorius N , Rutz W , McIntyre J S (2005) Schizophrenia practice guidelines: international survey and comparison . Br J Psychiatry 187: 248–255

Hirsch S R , Barnes T R (1994) Clinical use of high-dose neuroleptics . Br J Psychiatry 164: 94–96

Leucht S , Barnes T R , Kissling W , Engel R R , Correll C , Kane J M (2003a) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials . Am J Psychiatry 160: 1209–1222

Leucht S , Wahlbeck K , Hamann J , Kissling W (2003b) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis . Lancet 361: 1581–1589

Lieberman J A , Stroup T S , McEvoy J P , Swartz M S , Rosenheck R A , Perkins D O , Keefe R S , Davis S M , Davis C E , Lebowitz B D , Severe J , Hsiao J K , Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia . N Engl J Med 353: 1209–1223

NICE (2002) Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical Guideline 1, December 2002. National Institute for Clinical Excellence, London

Thakore J H (2005) Metabolic syndrome and schizophrenia . Br J Psychiatry 186: 45–46

Thompson C (1994) The use of high-dose antipsychotic medication . Br J Psychiatry 164: 448–458

Tunis S L , Johnstone B M , Gibson P J , Loosbrock D L , Dulisse B K (1999) Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia . J Clin Psychiatry 60 Suppl 19: 38–45 . discussion 46